Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000324,FHH-Chr 15BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0282,umol/l,0.004,0.0128,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54647,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0098,umol/l,0.002,0.0066,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54648,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000790,SS-Chr 10BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0108,umol/l,0.0015,0.0048,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54649,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,16,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0362,umol/l,0.0029,0.0115,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54650,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000323,FHH-Chr 14BN/Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0189,umol/l,0.0025,0.007,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54651,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000331,FHH-Chr 2BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0218,umol/l,0.0032,0.0096,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54652,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000334,FHH-Chr 5BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0236,umol/l,0.004,0.0128,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54653,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000795,SS-Chr 14BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1369,umol/l,0.0357,0.113,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54654,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000335,FHH-Chr 6BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0106,umol/l,0.0011,0.0035,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54655,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000806,SS-Chr 6BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0368,umol/l,0.0116,0.0348,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54656,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000809,SS-Chr 9BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0629,umol/l,0.0162,0.0511,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54657,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0821,umol/l,0.0206,0.0742,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54658,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000335,FHH-Chr 6BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0078,umol/l,0.0013,0.004,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54659,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000334,FHH-Chr 5BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0346,umol/l,0.0047,0.0148,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54660,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000795,SS-Chr 14BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1677,umol/l,0.0544,0.1633,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54661,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000809,SS-Chr 9BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0416,umol/l,0.0038,0.0122,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54662,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000806,SS-Chr 6BN/Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0304,umol/l,0.0063,0.0166,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54663,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0211,umol/l,0.0036,0.012,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54664,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000790,SS-Chr 10BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0146,umol/l,0.0039,0.0117,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54665,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000324,FHH-Chr 15BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0333,umol/l,0.0038,0.0119,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54666,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000323,FHH-Chr 14BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0203,umol/l,0.0028,0.0088,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54667,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000331,FHH-Chr 2BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0199,umol/l,0.0054,0.0163,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54668,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000798,SS-Chr 17BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0765,umol/l,0.0154,0.0487,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54669,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000319,FHH-Chr 10BN/Mcwi,female,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0053,umol/l,0.0014,0.0037,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54670,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000325,FHH-Chr 16BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0111,umol/l,0.0022,0.0069,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54671,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000807,SS-Chr 7BN/Mcwi,male,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0063,umol/l,8.0E-4,0.0027,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54672,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001108,GH/OmrMcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0172,umol/l,0.0067,0.015,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54673,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000326,FHH-Chr 17BN/Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0129,umol/l,0.0019,0.0053,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54674,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000798,SS-Chr 17BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0384,umol/l,0.0097,0.0307,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54675,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000805,SS-Chr 5BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0437,umol/l,0.0123,0.0388,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54676,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000326,FHH-Chr 17BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0142,umol/l,0.0028,0.009,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54677,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001108,GH/OmrMcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0597,umol/l,0.0244,0.0547,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54678,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000807,SS-Chr 7BN/Mcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0098,umol/l,0.0022,0.0075,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54679,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000338,FHH-Chr XBN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0106,umol/l,0.0019,0.0059,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54680,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000805,SS-Chr 5BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0574,umol/l,0.0151,0.0478,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54681,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000319,FHH-Chr 10BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0053,umol/l,7.0E-4,0.0021,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54682,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000338,FHH-Chr XBN/Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0102,umol/l,0.0011,0.003,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54683,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000325,FHH-Chr 16BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0209,umol/l,0.0049,0.0154,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54684,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000337,FHH-Chr 8BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0264,umol/l,0.0082,0.0247,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54685,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000801,SS-Chr 20BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0352,umol/l,0.0061,0.0183,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54686,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000328,FHH-Chr 19BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0117,umol/l,0.0027,0.0086,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54687,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000342,FHH/EurMcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0079,umol/l,0.0026,0.0074,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54688,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000797,SS-Chr 16BN/Mcwi,female,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0294,umol/l,0.0061,0.0229,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54689,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000332,FHH-Chr 3BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0117,umol/l,0.0016,0.0049,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54690,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000796,SS-Chr 15BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0623,umol/l,0.0128,0.0385,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54691,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000803,SS-Chr 3BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1141,umol/l,0.0162,0.0486,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54692,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000796,SS-Chr 15BN/Mcwi,female,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0501,umol/l,0.0096,0.0254,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54693,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000328,FHH-Chr 19BN/Mcwi,female,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0092,umol/l,0.0018,0.006,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54694,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000797,SS-Chr 16BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0113,umol/l,0.0053,0.0158,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54695,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000322,FHH-Chr 13BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0175,umol/l,0.009,0.0286,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54696,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000337,FHH-Chr 8BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0137,umol/l,0.0021,0.0066,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54697,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000803,SS-Chr 3BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0956,umol/l,0.0109,0.0345,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54698,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000794,SS-Chr 13BN/Mcwi,female,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0206,umol/l,0.0023,0.0075,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54699,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000322,FHH-Chr 13BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0337,umol/l,0.0075,0.0226,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54700,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000330,FHH-Chr 20BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0235,umol/l,0.0062,0.0185,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54701,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000327,FHH-Chr 18BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0087,umol/l,0.0011,0.0035,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54702,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000330,FHH-Chr 20BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0189,umol/l,0.0037,0.0117,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54703,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000801,SS-Chr 20BN/Mcwi,male,84 days to 70 days,26,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0391,umol/l,0.0105,0.0535,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54704,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000327,FHH-Chr 18BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0044,umol/l,5.0E-4,0.0015,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54705,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000792,SS-Chr 11BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0166,umol/l,0.0041,0.013,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54706,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000342,FHH/EurMcwi,male,84 days to 70 days,50,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0174,umol/l,0.0019,0.0135,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54707,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000794,SS-Chr 13BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0151,umol/l,0.0032,0.0096,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54708,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000332,FHH-Chr 3BN/Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0151,umol/l,0.0037,0.0098,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54709,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000339,FHH-Chr YBN/Mcwi,male,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0192,umol/l,0.0025,0.0109,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54710,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,17,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0335,umol/l,0.0056,0.0231,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54711,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000792,SS-Chr 11BN/Mcwi,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0256,umol/l,0.0112,0.0372,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54712,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000799,SS-Chr 18BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0409,umol/l,0.014,0.0443,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54713,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,85,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0582,umol/l,0.0142,0.1305,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54714,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001457,SS-Chr 1BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0163,umol/l,0.004,0.0128,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54715,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001109,SS-Chr XBN/Mcwi,female,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0101,umol/l,0.0026,0.0064,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54716,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000329,FHH-Chr 1BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0309,umol/l,0.0049,0.0148,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54717,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000799,SS-Chr 18BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0252,umol/l,0.0059,0.0185,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54718,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000333,FHH-Chr 4BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0349,umol/l,0.0076,0.024,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54719,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001457,SS-Chr 1BN/Mcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.039,umol/l,0.0325,0.1126,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54720,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000804,SS-Chr 4BN/Mcwi,male,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0481,umol/l,0.0087,0.0336,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54721,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.012,umol/l,0.0027,0.0084,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54722,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000320,FHH-Chr 11BN/Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0244,umol/l,0.0099,0.0262,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54723,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000333,FHH-Chr 4BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0166,umol/l,0.0028,0.0083,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54724,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000815,SS.BN-(D8Rat163-D8Rat81)/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0457,umol/l,0.007,0.0222,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54725,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000800,SS-Chr 19BN/Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0742,umol/l,0.0137,0.0363,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54726,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000793,SS-Chr 12BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0885,umol/l,0.0125,0.0374,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54727,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000320,FHH-Chr 11BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0204,umol/l,0.0045,0.0143,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54728,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000804,SS-Chr 4BN/Mcwi,female,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0634,umol/l,0.017,0.0638,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54729,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000800,SS-Chr 19BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0392,umol/l,0.0067,0.02,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54730,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000336,FHH-Chr 7BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0067,umol/l,0.001,0.0031,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54731,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001110,FHH-Chr 9BN/Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0051,umol/l,7.0E-4,0.002,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54732,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000802,SS-Chr 2BN/Mcwi,female,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0477,umol/l,0.0054,0.0236,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54733,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000815,SS.BN-(D8Rat163-D8Rat81)/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0505,umol/l,0.0114,0.0359,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54734,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000793,SS-Chr 12BN/Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.058,umol/l,0.0069,0.0195,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54735,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000145,BN/NHsdMcwi,male,84 days to 70 days,20,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1705,umol/l,0.0319,0.1425,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54736,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000145,BN/NHsdMcwi,female,84 days to 70 days,17,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1418,umol/l,0.0172,0.0711,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54737,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001109,SS-Chr XBN/Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0268,umol/l,0.0049,0.0138,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54738,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000336,FHH-Chr 7BN/Mcwi,male,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0096,umol/l,0.0013,0.005,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54739,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001110,FHH-Chr 9BN/Mcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0077,umol/l,0.0026,0.0059,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54740,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000802,SS-Chr 2BN/Mcwi,male,84 days to 70 days,18,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0611,umol/l,0.0133,0.0564,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54741,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000329,FHH-Chr 1BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0345,umol/l,0.0075,0.0236,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54742,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000324,FHH-Chr 15BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0205,umol/l,0.0032,0.0097,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54879,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0109,umol/l,0.0028,0.0095,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54880,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000790,SS-Chr 10BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0195,umol/l,0.0038,0.0119,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54881,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,male,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.064,umol/l,0.0138,0.0533,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54882,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000323,FHH-Chr 14BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0139,umol/l,0.0029,0.0092,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54883,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000331,FHH-Chr 2BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0242,umol/l,0.0053,0.0159,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54884,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000334,FHH-Chr 5BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0174,umol/l,0.0038,0.012,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54885,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000795,SS-Chr 14BN/Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0421,umol/l,0.016,0.0451,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54886,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000335,FHH-Chr 6BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0129,umol/l,0.0017,0.005,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54887,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000806,SS-Chr 6BN/Mcwi,female,84 days to 70 days,20,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0295,umol/l,0.006,0.0267,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54888,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000809,SS-Chr 9BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0943,umol/l,0.0349,0.1105,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54889,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000813,SS.BN-(D12Arb13-D12Rat79)/Mcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0749,umol/l,0.0152,0.0589,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54890,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000335,FHH-Chr 6BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0096,umol/l,0.0015,0.0046,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54891,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000334,FHH-Chr 5BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0201,umol/l,0.0028,0.0088,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54892,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000795,SS-Chr 14BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0758,umol/l,0.029,0.0918,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54893,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000809,SS-Chr 9BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0358,umol/l,0.0049,0.0147,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54894,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000806,SS-Chr 6BN/Mcwi,male,84 days to 70 days,21,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0359,umol/l,0.0108,0.0493,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54895,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,17,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0062,umol/l,0.0013,0.0055,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54896,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000790,SS-Chr 10BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0091,umol/l,0.001,0.0029,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54897,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000324,FHH-Chr 15BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0259,umol/l,0.0069,0.0207,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54898,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000323,FHH-Chr 14BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0207,umol/l,0.0033,0.01,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54899,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000331,FHH-Chr 2BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0216,umol/l,0.0036,0.0107,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54900,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000798,SS-Chr 17BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1096,umol/l,0.0192,0.0575,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54901,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000319,FHH-Chr 10BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0135,umol/l,0.0022,0.0069,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54902,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000325,FHH-Chr 16BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0118,umol/l,0.0037,0.0116,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54903,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000807,SS-Chr 7BN/Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.015,umol/l,0.0065,0.0184,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54904,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001108,GH/OmrMcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.078,umol/l,0.021,0.047,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54905,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000326,FHH-Chr 17BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0222,umol/l,0.0092,0.0292,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54906,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000798,SS-Chr 17BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1585,umol/l,0.0527,0.1582,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54907,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000805,SS-Chr 5BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0185,umol/l,0.0039,0.0116,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54908,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000326,FHH-Chr 17BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0118,umol/l,0.0021,0.0066,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54909,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001108,GH/OmrMcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0491,umol/l,0.0189,0.0423,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54910,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000807,SS-Chr 7BN/Mcwi,female,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0087,umol/l,0.0012,0.0041,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54911,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000338,FHH-Chr XBN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0191,umol/l,0.0043,0.0137,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54912,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000805,SS-Chr 5BN/Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0493,umol/l,0.0086,0.0228,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54913,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000319,FHH-Chr 10BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0177,umol/l,0.0025,0.008,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54914,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000338,FHH-Chr XBN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0265,umol/l,0.0063,0.0199,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54915,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000325,FHH-Chr 16BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0119,umol/l,0.0039,0.0124,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54916,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000337,FHH-Chr 8BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0193,umol/l,0.0055,0.0164,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54917,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000801,SS-Chr 20BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0454,umol/l,0.0082,0.026,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54918,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000328,FHH-Chr 19BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0054,umol/l,0.001,0.0031,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54919,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000342,FHH/EurMcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0239,umol/l,0.0051,0.0163,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54920,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000797,SS-Chr 16BN/Mcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0272,umol/l,0.006,0.0234,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54921,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000332,FHH-Chr 3BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0074,umol/l,9.0E-4,0.0029,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54922,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000796,SS-Chr 15BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0217,umol/l,0.0061,0.0184,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54923,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000803,SS-Chr 3BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0827,umol/l,0.0197,0.0592,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54924,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000796,SS-Chr 15BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0109,umol/l,0.0047,0.0149,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54925,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000328,FHH-Chr 19BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0897,umol/l,0.0836,0.2642,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54926,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000797,SS-Chr 16BN/Mcwi,male,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0228,umol/l,0.0041,0.0153,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54927,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000322,FHH-Chr 13BN/Mcwi,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0062,umol/l,0.0017,0.006,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54928,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000337,FHH-Chr 8BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0119,umol/l,0.0038,0.0121,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54929,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000803,SS-Chr 3BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0929,umol/l,0.0133,0.0421,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54930,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000794,SS-Chr 13BN/Mcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0774,umol/l,0.0304,0.1176,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54931,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000322,FHH-Chr 13BN/Mcwi,male,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.008,umol/l,0.0015,0.0052,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54932,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000330,FHH-Chr 20BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0226,umol/l,0.0022,0.0069,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54933,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000327,FHH-Chr 18BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0413,umol/l,0.0189,0.0597,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54934,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000330,FHH-Chr 20BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0195,umol/l,0.003,0.0094,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54935,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000801,SS-Chr 20BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0448,umol/l,0.0102,0.0324,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54936,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000327,FHH-Chr 18BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0307,umol/l,0.0131,0.0393,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54937,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000792,SS-Chr 11BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0242,umol/l,0.0057,0.0171,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54938,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000342,FHH/EurMcwi,male,84 days to 70 days,54,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0508,umol/l,0.0242,0.178,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54939,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000794,SS-Chr 13BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0118,umol/l,0.0033,0.0105,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54940,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000332,FHH-Chr 3BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0063,umol/l,0.0014,0.0041,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54941,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000339,FHH-Chr YBN/Mcwi,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0186,umol/l,0.0033,0.0109,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54942,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000810,SS-Chr YBN/Mcwi,male,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0385,umol/l,0.0044,0.0191,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54943,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000792,SS-Chr 11BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0228,umol/l,0.0062,0.0197,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54944,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000799,SS-Chr 18BN/Mcwi,male,84 days to 70 days,21,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0121,umol/l,0.0023,0.0106,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54945,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,90,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0571,umol/l,0.0062,0.0591,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54946,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001109,SS-Chr XBN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0088,umol/l,0.0041,0.0131,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54947,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000329,FHH-Chr 1BN/Mcwi,male,84 days to 70 days,24,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1901,umol/l,0.0455,0.2231,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54948,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000799,SS-Chr 18BN/Mcwi,female,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0185,umol/l,0.0064,0.0277,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54949,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000333,FHH-Chr 4BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0234,umol/l,0.0069,0.0218,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54950,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000804,SS-Chr 4BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0572,umol/l,0.0256,0.081,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54951,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0781,umol/l,0.0165,0.0639,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54952,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000320,FHH-Chr 11BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0076,umol/l,0.0015,0.0046,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54953,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000333,FHH-Chr 4BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0154,umol/l,0.004,0.0119,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54954,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000815,SS.BN-(D8Rat163-D8Rat81)/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0124,umol/l,0.003,0.0096,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54955,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000800,SS-Chr 19BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0395,umol/l,0.007,0.022,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54956,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000793,SS-Chr 12BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0577,umol/l,0.0089,0.0281,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54957,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000320,FHH-Chr 11BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0081,umol/l,0.0019,0.006,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54958,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000804,SS-Chr 4BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0357,umol/l,0.0163,0.0516,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54959,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000800,SS-Chr 19BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0444,umol/l,0.0078,0.0245,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54960,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000336,FHH-Chr 7BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.006,umol/l,9.0E-4,0.0026,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54961,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001110,FHH-Chr 9BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0061,umol/l,0.0027,0.0082,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54962,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000802,SS-Chr 2BN/Mcwi,female,84 days to 70 days,16,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0605,umol/l,0.0051,0.0203,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54963,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000815,SS.BN-(D8Rat163-D8Rat81)/Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0078,umol/l,0.0024,0.0068,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54964,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000793,SS-Chr 12BN/Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0341,umol/l,0.0055,0.0166,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54965,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000145,BN/NHsdMcwi,male,84 days to 70 days,20,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.3078,umol/l,0.1235,0.5524,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54966,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000145,BN/NHsdMcwi,female,84 days to 70 days,24,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1883,umol/l,0.0487,0.2388,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54967,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001109,SS-Chr XBN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0096,umol/l,0.0029,0.0086,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54968,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000336,FHH-Chr 7BN/Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0082,umol/l,0.0018,0.0051,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54969,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0001110,FHH-Chr 9BN/Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0065,umol/l,0.002,0.006,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54970,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000802,SS-Chr 2BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.038,umol/l,0.0094,0.0298,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54971,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000329,FHH-Chr 1BN/Mcwi,female,84 days to 70 days,26,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1658,umol/l,0.0395,0.2016,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54972,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000799,SS-Chr 18BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.029,umol/l,0.0041,0.0129,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54985,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.3757,umol/l,0.1379,0.4972,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54986,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000342,FHH/EurMcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0523,umol/l,0.0095,0.0302,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54987,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000797,SS-Chr 16BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.8944,umol/l,0.1462,0.4623,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54988,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000730,SHR/NCrl,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1868,umol/l,0.0589,0.1863,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54989,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000799,SS-Chr 18BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0413,umol/l,0.0059,0.0187,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54990,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0001108,GH/OmrMcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1671,umol/l,0.0261,0.0825,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54991,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000797,SS-Chr 16BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.5258,umol/l,0.0972,0.3073,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54992,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000342,FHH/EurMcwi,male,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0466,umol/l,0.0158,0.0386,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54993,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.6314,umol/l,0.2761,0.9563,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54994,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000730,SHR/NCrl,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.3069,umol/l,0.1078,0.3408,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54995,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0001108,GH/OmrMcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1598,umol/l,0.0139,0.0417,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54996,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.07,umol/l,0.0086,0.0298,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55123,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000342,FHH/EurMcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0428,umol/l,0.0071,0.0158,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55124,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000797,SS-Chr 16BN/Mcwi,female,84 days to 70 days,4,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.03,umol/l,0.0035,0.007,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55125,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000730,SHR/NCrl,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0548,umol/l,0.0097,0.0274,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55126,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000342,FHH/EurMcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0322,umol/l,0.0092,0.0207,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55127,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0606,umol/l,0.0077,0.023,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55128,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000730,SHR/NCrl,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0345,umol/l,0.0052,0.0163,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55129,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001131,FHH-Nr0b2m1Mcwi,female,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0069,umol/l,0.003,0.0052,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62732,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001134,FHH-Adipoqm1Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0093,umol/l,0.0023,0.0073,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62733,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001133,FHH-Adipoqm2Mcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0161,umol/l,0.0032,0.0125,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62734,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001121,FHH-Tgfbr2m2Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0063,umol/l,8.0E-4,0.0024,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62735,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001295,F344-Trpc4Tn(sb-T2/Bart3)2.192Mcwi,male,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0342,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62736,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001126,FHH-Lcatm1Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0213,umol/l,0.0078,0.022,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62737,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001280,F344-Elmod3Tn(sb-T2/Bart3)2.42Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0078,umol/l,0.002,0.0054,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62738,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001130,FHH-Agtr1bm1Mcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0073,umol/l,0.0019,0.0042,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62739,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001121,FHH-Tgfbr2m2Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0079,umol/l,0.001,0.003,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62740,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001274,F344-Plce1Tn(sb-T2/Bart3)2.146Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0078,umol/l,0.0038,0.0107,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62741,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001295,F344-Trpc4Tn(sb-T2/Bart3)2.192Mcwi,female,84 days to 70 days,2,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0072,umol/l,0.0014,0.002,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62742,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001126,FHH-Lcatm1Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.044,umol/l,0.0214,0.0676,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62743,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001120,FHH-Slc8a2m1Mcwi,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0123,umol/l,0.0036,0.0131,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62744,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001280,F344-Elmod3Tn(sb-T2/Bart3)2.42Mcwi,female,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0086,umol/l,8.0E-4,0.0015,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62745,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001130,FHH-Agtr1bm1Mcwi,female,84 days to 70 days,4,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0081,umol/l,9.0E-4,0.0019,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62746,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001131,FHH-Nr0b2m1Mcwi,male,84 days to 70 days,4,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0095,umol/l,0.0044,0.0087,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62747,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001123,BN-Tgfbr2m1Mcwi,male,84 days to 70 days,2,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0178,umol/l,0.0043,0.006,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62748,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001134,FHH-Adipoqm1Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0107,umol/l,0.0018,0.005,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62749,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001274,F344-Plce1Tn(sb-T2/Bart3)2.146Mcwi,female,84 days to 70 days,4,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0083,umol/l,0.0061,0.0121,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62750,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001133,FHH-Adipoqm2Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0144,umol/l,0.004,0.0106,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62751,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001140,FHH-Ccr2m1Mcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0078,umol/l,5.0E-4,0.001,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62752,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001124,FHH-F10m1Mcwi,female,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0299,umol/l,0.008,0.0212,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62753,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001246,F344-Brinp3Tn(sb-T2/Bart3)2.189Mcwi,male,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.011,umol/l,0.0054,0.0093,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62754,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001122,FHH-Procm1Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0577,umol/l,0.0216,0.061,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62755,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001151,FHH-Htr1am1Mcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.031,umol/l,0.0082,0.0284,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62756,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0112,umol/l,0.0035,0.0104,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62757,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001142,FHH-F10m2Mcwi,male,84 days to 70 days,17,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0129,umol/l,0.0022,0.0093,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62758,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001246,F344-Brinp3Tn(sb-T2/Bart3)2.189Mcwi,female,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0057,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62759,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001140,FHH-Ccr2m1Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0118,umol/l,0.0037,0.0105,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62760,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001132,FHH-Nr4a1m1Mcwi,male,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0062,umol/l,0.0015,0.0038,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62761,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001122,FHH-Procm1Mcwi,male,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0314,umol/l,0.0116,0.0448,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62762,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001278,F344-Lims1Tn(sb-T2/Bart3)2.169Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0077,umol/l,0.002,0.0058,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62763,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001151,FHH-Htr1am1Mcwi,male,84 days to 70 days,18,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0378,umol/l,0.0094,0.0398,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62764,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001278,F344-Lims1Tn(sb-T2/Bart3)2.169Mcwi,male,84 days to 70 days,4,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0072,umol/l,0.0019,0.0039,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62765,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0105,umol/l,0.0041,0.0122,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62766,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001142,FHH-F10m2Mcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.007,umol/l,0.0016,0.0054,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62767,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001124,FHH-F10m1Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0071,umol/l,0.0012,0.0032,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62768,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001132,FHH-Nr4a1m1Mcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0061,umol/l,6.0E-4,0.0013,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62769,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001626,F344-DccTn(sb-T2/Bart3)2.205Mcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0101,umol/l,0.0048,0.0107,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62770,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001269,F344-Myo9aTn(sb-T2/Bart3)2.186Mcwi,male,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0089,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62771,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001269,F344-Myo9aTn(sb-T2/Bart3)2.186Mcwi,female,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0093,umol/l,0.0019,0.0033,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62772,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001264,F344-Fam19a2Tn(sb-T2/Bart3)2.184Mcwi,male,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0106,umol/l,0.0031,0.0054,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62773,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000342,FHH/EurMcwi,female,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0094,umol/l,0.003,0.0073,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62774,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001193,BN-Lcatm3Mcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0218,umol/l,0.0075,0.0168,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62775,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001273,F344-Plcb3Tn(sb-T2/Bart3)2.69Mcwi,male,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0068,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62776,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001264,F344-Fam19a2Tn(sb-T2/Bart3)2.184Mcwi,female,84 days to 70 days,2,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0044,umol/l,0.0024,0.0034,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62777,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001193,BN-Lcatm3Mcwi,male,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0183,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62778,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001273,F344-Plcb3Tn(sb-T2/Bart3)2.69Mcwi,female,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0031,umol/l,0.0015,0.0026,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62779,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001119,FHH-Ghsrm1Mcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.003,umol/l,4.0E-4,8.0E-4,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62780,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001626,F344-DccTn(sb-T2/Bart3)2.205Mcwi,male,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0089,umol/l,0.0026,0.0069,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62781,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001127,FHH-Egln3m1Mcwi,male,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0334,umol/l,0.0117,0.0285,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62782,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001135,FHH-Adipoqm3Mcwi,female,84 days to 70 days,7,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0068,umol/l,0.0023,0.0062,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62783,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001135,FHH-Adipoqm3Mcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0074,umol/l,0.0047,0.0105,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62784,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000342,FHH/EurMcwi,male,84 days to 70 days,119,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0129,umol/l,0.0014,0.0153,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62785,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001128,FHH-Adra1am1Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0227,umol/l,0.0082,0.0233,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62786,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001234,F344-AbatTn(sb-T2/Bart3)2.163Mcwi,female,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0013,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62787,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001128,FHH-Adra1am1Mcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.023,umol/l,0.0107,0.0303,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62788,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001116,FHH-Tlr4m1Mcwi,male,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0056,umol/l,0.0011,0.0038,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62789,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001234,F344-AbatTn(sb-T2/Bart3)2.163Mcwi,male,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0024,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62790,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001287,F344-Stxbp5lTn(sb-T2/Bart3)2.202Mcwi,female,84 days to 70 days,2,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0056,umol/l,3.0E-4,4.0E-4,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62791,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001120,FHH-Slc8a2m1Mcwi,male,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0226,umol/l,0.0075,0.0289,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62792,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001116,FHH-Tlr4m1Mcwi,female,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0075,umol/l,0.0015,0.005,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62793,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001623,F344-Erbb4Tn(sb-T2/Bart3)2.208Mcwi,female,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0142,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62794,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001127,FHH-Egln3m1Mcwi,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0291,umol/l,0.0105,0.0378,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62795,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001260,F344-Inpp4bTn(sb-T2/Bart3)2.143Mcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0049,umol/l,0.0016,0.0046,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62796,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001271,F344-Nrg1Tn(sb-T2/Bart3)2.183Mcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0098,umol/l,0.0019,0.0043,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62797,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000145,BN/NHsdMcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0123,umol/l,0.0022,0.0063,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62798,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001271,F344-Nrg1Tn(sb-T2/Bart3)2.183Mcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.007,umol/l,0.0018,0.004,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62799,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000145,BN/NHsdMcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0074,umol/l,5.0E-4,0.0011,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62800,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001287,F344-Stxbp5lTn(sb-T2/Bart3)2.202Mcwi,male,84 days to 70 days,3,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.017,umol/l,0.005,0.0086,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62801,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001467,SS-Ghsrm3Mcwi,male,84 days to 70 days,1,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.011,umol/l,,,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62968,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001463,SS-Cpt2m1Mcwi,male,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0225,umol/l,0.0043,0.0095,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62969,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0226,umol/l,0.0034,0.0112,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62970,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001480,SS-Sod3m1Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0087,umol/l,0.0019,0.0057,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62971,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001475,SS-Klf4m3Mcwi,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0195,umol/l,0.0073,0.022,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62972,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001475,SS-Klf4m3Mcwi,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0138,umol/l,0.0048,0.0144,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62973,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001463,SS-Cpt2m1Mcwi,female,84 days to 70 days,2,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0318,umol/l,0.0033,0.0047,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62974,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001467,SS-Ghsrm3Mcwi,female,84 days to 70 days,2,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.013,umol/l,0.0022,0.0032,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62975,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.017,umol/l,0.0042,0.0094,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62976,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
528,PhysGen Vascular data,vasoconstriction trait,,RS:0001480,SS-Sod3m1Mcwi,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0081,umol/l,7.0E-4,0.0024,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (1 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62977,controlled sodium content diet (1 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Dyets upon arrival at MCW. For rats received from Harlan",RS:0000698,Hsd:SD,male,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0932,umol/l,0.0226,0.0846,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56835,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Dyets upon arrival at MCW. For rats received from Harlan",RS:0000698,Hsd:SD,female,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.2491,umol/l,0.1275,0.5556,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56836,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000799,SS-Chr 18BN/Mcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1047,umol/l,0.0179,0.0567,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56874,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.2078,umol/l,0.1401,0.4646,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56875,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000342,FHH/EurMcwi,female,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.7388,umol/l,0.121,0.3422,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56876,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000797,SS-Chr 16BN/Mcwi,female,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.2095,umol/l,0.089,0.218,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56877,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000730,SHR/NCrl,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0674,umol/l,0.0278,0.0835,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56878,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000799,SS-Chr 18BN/Mcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1114,umol/l,0.021,0.0665,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56879,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0001108,GH/OmrMcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1028,umol/l,0.0376,0.1189,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56880,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000797,SS-Chr 16BN/Mcwi,male,84 days to 70 days,6,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.217,umol/l,0.0863,0.2114,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56881,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000342,FHH/EurMcwi,male,84 days to 70 days,8,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.6332,umol/l,0.1477,0.4177,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56882,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1881,umol/l,0.0712,0.2759,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56883,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0000730,SHR/NCrl,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0815,umol/l,0.0212,0.0671,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56884,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Dyets,RS:0001108,GH/OmrMcwi,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.1053,umol/l,0.0291,0.0921,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56885,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000731,WKY/NCrl,male,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0353,umol/l,0.0051,0.019,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56997,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000509,LEW/Crl,female,84 days to 70 days,23,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0475,umol/l,0.0046,0.022,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56998,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000064,Crl:CD(SD),male,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0188,umol/l,0.0042,0.0184,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56999,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000179,F344/DuCrl,male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0639,umol/l,0.0096,0.0304,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57000,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000064,Crl:CD(SD),female,84 days to 70 days,19,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0272,umol/l,0.0044,0.019,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57001,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000436,LE/BluGill,female,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0158,umol/l,0.0054,0.0196,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57002,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000509,LEW/Crl,male,84 days to 70 days,24,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0615,umol/l,0.0076,0.0375,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57003,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000731,WKY/NCrl,female,84 days to 70 days,20,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.04,umol/l,0.0054,0.0241,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57004,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000179,F344/DuCrl,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0553,umol/l,0.0075,0.0238,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57005,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000436,LE/BluGill,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0162,umol/l,0.0036,0.0119,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57006,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Dyets upon arrival at MCW. For rats received from Harlan",RS:0000698,Hsd:SD,male,84 days to 70 days,13,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0641,umol/l,0.015,0.0541,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57195,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Dyets upon arrival at MCW. For rats received from Harlan",RS:0000698,Hsd:SD,female,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0406,umol/l,0.0076,0.0283,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57196,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000811,SS/JrHsdMcwi,male,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0517,umol/l,0.0097,0.0337,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57302,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000797,SS-Chr 16BN/Mcwi,female,84 days to 70 days,5,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.039,umol/l,0.0096,0.0215,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57303,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Conversion period. Moms had mixed diet, Dyets and Teklad, for 3-4 weeks. Whatever Mom was fed, so were pups. Whatever pups were fed in the barrier, they continued with through the study. Possible maternal influence on pups estimated at 10 weeks",RS:0000811,SS/JrHsdMcwi,female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0816,umol/l,0.0169,0.0534,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57304,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000731,WKY/NCrl,male,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0471,umol/l,0.0073,0.0272,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57425,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000509,LEW/Crl,female,84 days to 70 days,25,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.041,umol/l,0.0055,0.0275,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57426,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000064,Crl:CD(SD),male,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0232,umol/l,0.0053,0.0168,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57427,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000179,F344/DuCrl,male,84 days to 70 days,20,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0375,umol/l,0.0054,0.024,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57428,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000064,Crl:CD(SD),female,84 days to 70 days,10,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0522,umol/l,0.0221,0.0699,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57429,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000436,LE/BluGill,female,84 days to 70 days,15,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0023,umol/l,2.0E-4,9.0E-4,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57430,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000509,LEW/Crl,male,84 days to 70 days,24,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0487,umol/l,0.0059,0.0289,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57431,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000731,WKY/NCrl,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0367,umol/l,0.0059,0.0178,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57432,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000179,F344/DuCrl,female,84 days to 70 days,20,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0309,umol/l,0.0047,0.0212,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57433,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)
522,PhysGen Vascular data,vasoconstriction trait,"Moms were fed vendors standard diet, pups were fed Teklad upon arrival at MCW. For rats received from CRL and Harlan",RS:0000436,LE/BluGill,male,84 days to 70 days,14,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0054,umol/l,0.001,0.0038,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),57434,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours)